BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Iio E, Shimada N, Abe H, Atsukawa M, Yoshizawa K, Takaguchi K, Eguchi Y, Nomura H, Kuramitsu T, Kang J, Matsui T, Hirashima N, Tsubota A, Kusakabe A, Hasegawa I, Miyaki T, Shinkai N, Fujiwara K, Nojiri S, Tanaka Y. Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1. J Gastroenterol 2017;52:94-103. [DOI: 10.1007/s00535-016-1225-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Mawatari S, Oda K, Tabu K, Ijuin S, Kumagai K, Inada Y, Uto H, Hiramine Y, Kure T, Fujisaki K, Hashiguchi M, Hori T, Oshige A, Imanaka D, Saishoji A, Taniyama O, Sakae H, Tamai T, Moriuchi A, Ido A. New resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir. J Gastroenterol 2017;52:855-67. [DOI: 10.1007/s00535-016-1303-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
2 Ji F, Wei B, Yeo YH, Ogawa E, Zou B, Stave CD, Li Z, Dang S, Furusyo N, Cheung RC, Nguyen MH. Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia. Aliment Pharmacol Ther 2018;47:550-62. [PMID: 29327780 DOI: 10.1111/apt.14507] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 8.8] [Reference Citation Analysis]
3 Kanda T, Yasui S, Nakamura M, Suzuki E, Arai M, Ooka Y, Ogasawara S, Chiba T, Saito T, Haga Y. Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors. Int J Mol Sci. 2017;18. [PMID: 28441362 DOI: 10.3390/ijms18050906] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
4 Xia H, Lu C, Wang Y, Zaongo SD, Hu Y, Wu Y, Yan Z, Ma P. Efficacy and Safety of Direct-Acting Antiviral Therapy in Patients With Chronic Hepatitis C Virus Infection: A Real-World Single-Center Experience in Tianjin, China. Front Pharmacol 2020;11:710. [PMID: 32508646 DOI: 10.3389/fphar.2020.00710] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Liu Z, Mao X, Wu J, Yu K, Yang Q, Suo C, Lu M, Jin L, Zhang T, Chen X. World-wide Prevalence of Substitutions in HCV Genome Associated With Resistance to Direct-Acting Antiviral Agents. Clinical Gastroenterology and Hepatology 2021;19:1906-1914.e25. [DOI: 10.1016/j.cgh.2019.10.046] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
6 Honda M, Sugawara Y, Watanabe T, Tateyama M, Tanaka M, Uchida K, Kawabata S, Yoshii D, Miura K, Isono K, Hayashida S, Ohya Y, Yamamoto H, Sasaki Y, Inomata Y. Outcomes of treatment with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation. Hepatol Res 2017;47:1147-54. [PMID: 28002876 DOI: 10.1111/hepr.12853] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
7 Mawatari S, Oda K, Tabu K, Ijuin S, Kumagai K, Fujisaki K, Hashiguchi M, Inada Y, Uto H, Hiramine Y, Kure T, Hori T, Taniyama O, Kasai A, Tamai T, Moriuchi A, Ido A. The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvir. PLoS One 2018;13:e0198642. [PMID: 29856885 DOI: 10.1371/journal.pone.0198642] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
8 Mundim AEFM, de Castro FOF, Albuquerque MBB, Vilanova-Costa CAST, Pfrimer IAH, Silva AMTC. Major mutations in the NS3 gene region of hepatitis C virus related to the resistance to direct acting antiviral drugs: a systematic review. Virusdisease 2020;31:220-8. [PMID: 32904849 DOI: 10.1007/s13337-020-00616-9] [Reference Citation Analysis]
9 Parczewski M, Janczewska E, Pisula A, Dybowska D, Łojewski W, Witor A, Wawrzynowicz-Syczewska M, Socha Ł, Krygier R, Knysz B, Musialik J, Urbańska A, Scheibe K, Jaroszewicz J. HCV resistance-associated substitutions following direct-acting antiviral therapy failure - Real-life data from Poland. Infect Genet Evol 2021;93:104949. [PMID: 34087494 DOI: 10.1016/j.meegid.2021.104949] [Reference Citation Analysis]
10 Sagnelli E, Starace M, Minichini C, Pisaturo M, Macera M, Sagnelli C, Coppola N. Resistance detection and re-treatment options in hepatitis C virus-related chronic liver diseases after DAA-treatment failure. Infection 2018;46:761-83. [DOI: 10.1007/s15010-018-1188-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
11 Wei L, Omata M, Lim Y, Xie Q, Hou JL, Jia J, Hedskog C, Martin R, Doehle B, Yang J, De-oertel S, Massetto B, Kersey K, Brainard DM, Svarovskaia E, Mo H, Han K, Mizokami M, Duan Z. HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China. Antiviral Research 2018;158:178-84. [DOI: 10.1016/j.antiviral.2018.08.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
12 Alavian SM, Rezaee-Zavareh MS. Daclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-Analysis. Hepat Mon 2016;16:e41077. [PMID: 27826322 DOI: 10.5812/hepatmon.41077] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
13 Ishigami M, Hayashi K, Honda T, Kuzuya T, Ishizu Y, Ishikawa T, Nakano I, Urano F, Kumada T, Yoshioka K. Daclatasvir and asunaprevir treatment in patients infected by genotype 1b of hepatitis C virus with no or subtle resistant associated substitutions (RAS) in NS5A-Y93. J Med Virol. 2018;90:736-744. [PMID: 29111616 DOI: 10.1002/jmv.24978] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
14 Li Z, Chen ZW, Li H, Ren H, Hu P. Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China. Infect Drug Resist 2017;10:377-92. [PMID: 29184422 DOI: 10.2147/IDR.S146595] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 3.4] [Reference Citation Analysis]
15 Iio E, Shimada N, Takaguchi K, Senoh T, Eguchi Y, Atsukawa M, Tsubota A, Abe H, Kato K, Kusakabe A. Clinical evaluation of sofosbuvir/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir/asunaprevir therapy. Hepatol Res. 2017;. [PMID: 28332272 DOI: 10.1111/hepr.12898] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
16 Dinu S, Țârdei G, Ceaușu E, Florescu SA, Micu L, Ecobici AM, Mihăilă M, Oprișan G. Detection of anti-protease inhibitors resistance mutations in HCV strains infecting treatment-naïve chronic patients from Romania. Revista Romana de Medicina de Laborator 2018;26:443-9. [DOI: 10.2478/rrlm-2018-0029] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Cao W, Geng ZZ, Wang N, Pan Q, Guo S, Xu S, Zhou J, Liu WR. A Reversible Chemogenetic Switch for Chimeric Antigen Receptor T Cells**. Angewandte Chemie. [DOI: 10.1002/ange.202109550] [Reference Citation Analysis]
18 Ikegami T, Ueda Y, Akamatsu N, Ishiyama K, Goto R, Soyama A, Kuramitsu K, Honda M, Shinoda M, Yoshizumi T, Okajima H, Kitagawa Y, Inomata Y, Ku Y, Eguchi S, Taketomi A, Ohdan H, Kokudo N, Shimada M, Yanaga K, Furukawa H, Uemoto S, Maehara Y. Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation: A Japanese multicenter experience. Clin Transplant. 2017;31. [PMID: 28881052 DOI: 10.1111/ctr.13109] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
19 Bourlière M, Gordon SC, Schiff ER, Tran TT, Ravendhran N, Landis CS, Hyland RH, Stamm LM, Zhang J, Dvory-Sobol H, Subramanian GM, Brainard DM, McHutchison JG, Serfaty L, Thompson AJ, Sepe TE, Curry MP, Reddy KR, Manns MP. Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1. Lancet Gastroenterol Hepatol 2018;3:559-65. [PMID: 29859740 DOI: 10.1016/S2468-1253(18)30118-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
20 Toyoda H, Atsukawa M, Takaguchi K, Senoh T, Michitaka K, Hiraoka A, Fujioka S, Kondo C, Okubo T, Uojima H, Tada T, Yoneyama H, Watanabe T, Asano T, Ishikawa T, Tamai H, Abe H, Kato K, Tsuji K, Ogawa C, Shimada N, Iio E, Deguchi A, Itobayashi E, Mikami S, Moriya A, Okubo H, Tani J, Tsubota A, Tanaka Y, Masaki T, Iwakiri K, Kumada T. Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan. J Gastroenterol 2018;53:1276-84. [PMID: 29740665 DOI: 10.1007/s00535-018-1473-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
21 Takaguchi K, Toyoda H, Tsutsui A, Suzuki Y, Nakamuta M, Imamura M, Senoh T, Nagano T, Tada T, Tachi Y, Hiraoka A, Michitaka K, Shibata H, Joko K, Okubo H, Tsuji K, Takaki S, Watanabe T, Ogawa C, Chayama K, Kumada T, Kudo M, Kumada H. Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan. J Gastroenterol 2019;54:742-51. [DOI: 10.1007/s00535-019-01568-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
22 Taki S, Tamai H, Ida Y, Shingaki N, Kawashima A, Shimizu R, Moribata K, Maekita T, Iguchi M, Kato J, Nakao T, Kitano M. The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients. Gut Liver 2018;12:86-93. [PMID: 28798288 DOI: 10.5009/gnl17048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
23 Kato K, Shimada N, Atsukawa M, Abe H, Itokawa N, Matsumoto Y, Agata R, Tsubota A. Single nucleotide polymorphisms associated with elevated alanine aminotransferase in patients receiving asunaprevir plus daclatasvir combination therapy for chronic hepatitis C. PLoS One 2019;14:e0219022. [PMID: 31291311 DOI: 10.1371/journal.pone.0219022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
24 Tamori A, Hai H, Uchida-Kobayashi S, Enomoto M, Kozuka R, Motoyama H, Kawamura E, Hagihara A, Teranishi Y, Yoshida K, Morikawa H, Murakami Y, Kawada N. Outcomes for Cirrhotic Patients with Hepatitis C Virus 1b Treated with Asunaprevir and Daclatasvir Combination. Ann Hepatol 2017;16:734-41. [PMID: 28809743 DOI: 10.5604/01.3001.0010.2732] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
25 Kozuka R, Hai H, Motoyama H, Hagihara A, Fujii H, Uchida-Kobayashi S, Morikawa H, Enomoto M, Murakami Y, Kawada N, Tamori A. The presence of multiple NS5A RASs is associated with the outcome of sofosbuvir and ledipasvir therapy in NS5A inhibitor-naïve patients with chronic HCV genotype 1b infection in a real-world cohort. J Viral Hepat 2018;25:535-42. [PMID: 29274188 DOI: 10.1111/jvh.12850] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
26 Parczewski M, Cielniak I, Kordek J, Aksak-wąs B, Urbańska A, Leszczyszyn-pynka M, Siwak E, Bociąga-jasik M, Nowak A, Szymczak A, Zalewska M, Łojewski W, Vandamme A, Lübke N, Cuypers L. Transmission Networks of HCV Genotype 1a Enriched With Pre-existing Polymorphism Q80K Among HIV-Infected Patients With Acute Hepatitis C in Poland. JAIDS Journal of Acquired Immune Deficiency Syndromes 2018;77:514-22. [DOI: 10.1097/qai.0000000000001628] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
27 Hirayama T, Ikegami T, Honda A, Miyazaki T, Yara SI, Kohjima M, Nakamuta M, Matsuzaki Y. Differences in the Serum 4β-hydroxycholesterol Levels of Patients with Chronic Hepatitis C Virus (HCV) Infection: A Possible Impact on the Efficacy and Safety of Interferon (IFN)-free Treatment. Intern Med 2018;57:1219-27. [PMID: 29279486 DOI: 10.2169/internalmedicine.9479-17] [Reference Citation Analysis]
28 Izumi N, Takehara T, Chayama K, Yatsuhashi H, Takaguchi K, Ide T, Kurosaki M, Ueno Y, Toyoda H, Kakizaki S, Tanaka Y, Kawakami Y, Enomoto H, Ikeda F, Jiang D, De-Oertel S, McNabb BL, Camus G, Stamm LM, Brainard DM, McHutchison JG, Mochida S, Mizokami M. Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals. Hepatol Int 2018;12:356-67. [PMID: 30030720 DOI: 10.1007/s12072-018-9878-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
29 Xia H, Zhang Y, Zaongo SD, Liang J, Gong X, Hu Y, Ma P, Wang F. Direct-acting antiviral treatments display excellent outcomes even in older HCV-infected patients at increased risk of fibrosis. Ann Transl Med 2021;9:847. [PMID: 34164481 DOI: 10.21037/atm-21-1297] [Reference Citation Analysis]
30 Lobato CMO, Codes L, Silva GF, Souza AFM, Coelho HSM, Pedroso MLA, Parise ER, Lima LMSTB, Borba LA, Evangelista AS, Rezende REF, Cheinquer H, Kuniyoshi ASO, Aires RS, Quintela EHD, Mendes LSC, Nascimento FCV, Medeiros Filho JEM, Ferraz MLCG, Abdala E, Bittencourt PL; Members of the Brazilian Real-Life Study about HCV treatment., Members of the Brazilian Real-Life Study about HCV treatment. Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil. Ann Hepatol 2019;18:849-54. [PMID: 31537509 DOI: 10.1016/j.aohep.2019.08.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
31 Ji F, Yeo YH, Wei MT, Ogawa E, Enomoto M, Lee DH, Iio E, Lubel J, Wang W, Wei B, Ide T, Preda CM, Conti F, Minami T, Bielen R, Sezaki H, Barone M, Kolly P, Chu PS, Virlogeux V, Eurich D, Henry L, Bass MB, Kanai T, Dang S, Li Z, Dufour JF, Zoulim F, Andreone P, Cheung RC, Tanaka Y, Furusyo N, Toyoda H, Tamori A, Nguyen MH. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. J Hepatol 2019;71:473-85. [PMID: 31096005 DOI: 10.1016/j.jhep.2019.04.017] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 10.0] [Reference Citation Analysis]
32 Maekawa S, Sato M, Kuratomi N, Inoue T, Suzuki Y, Tatsumi A, Miura M, Matsuda S, Muraoka M, Nakakuki N, Amemiya F, Takano S, Fukasawa M, Nakayama Y, Yamaguchi T, Sato T, Sakamoto M, Murakawa M, Nakagawa M, Asahina Y, Enomoto N. Association between alanine aminotransferase elevation and UGT1A1*6 polymorphisms in daclatasvir and asunaprevir combination therapy for chronic hepatitis C. J Gastroenterol 2018;53:780-6. [PMID: 29094205 DOI: 10.1007/s00535-017-1405-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
33 Suda G, Ogawa K, Yamamoto Y, Katagiri M, Furuya K, Kumagai K, Konno J, Kimura M, Kawagishi N, Ohara M. Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy. J Gastroenterol. 2017;52:1122-1129. [PMID: 28315983 DOI: 10.1007/s00535-017-1328-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]